Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 5%

Structure Therapeutics Inc. (NASDAQ:GPCR) shares were down 5% during trading on Monday . The company traded as low as $38.50 and last traded at $38.79. Approximately 110,941 shares traded hands during mid-day trading, a decline of 86% from the average daily volume of 787,334 shares. The stock had previously closed at $40.84.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on GPCR shares. JPMorgan Chase & Co. started coverage on Structure Therapeutics in a research note on Tuesday, May 21st. They issued an “overweight” rating and a $65.00 price target on the stock. JMP Securities reduced their target price on shares of Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a research report on Friday, August 9th. Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 price objective on shares of Structure Therapeutics in a research note on Monday. Finally, BMO Capital Markets lifted their target price on shares of Structure Therapeutics from $83.00 to $100.00 and gave the company an “outperform” rating in a report on Friday, June 7th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $84.63.

Structure Therapeutics Stock Down 1.1 %

The stock has a market cap of $1.88 billion, a PE ratio of -50.66 and a beta of -3.52. The stock’s fifty day moving average price is $38.12 and its 200 day moving average price is $39.67.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.05. On average, equities research analysts expect that Structure Therapeutics Inc. will post -0.86 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP increased its stake in shares of Structure Therapeutics by 404.0% in the 4th quarter. Wellington Management Group LLP now owns 4,372,326 shares of the company’s stock worth $178,216,000 after purchasing an additional 3,504,747 shares in the last quarter. Avoro Capital Advisors LLC raised its stake in shares of Structure Therapeutics by 133.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,333,333 shares of the company’s stock worth $95,107,000 after buying an additional 1,333,333 shares during the period. RA Capital Management L.P. raised its stake in shares of Structure Therapeutics by 210.2% in the first quarter. RA Capital Management L.P. now owns 1,510,362 shares of the company’s stock worth $64,734,000 after buying an additional 1,023,530 shares during the period. Capital International Investors bought a new position in shares of Structure Therapeutics during the 4th quarter valued at approximately $34,647,000. Finally, Capital Research Global Investors increased its holdings in Structure Therapeutics by 182.3% in the 4th quarter. Capital Research Global Investors now owns 973,535 shares of the company’s stock worth $39,681,000 after acquiring an additional 628,687 shares in the last quarter. Institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.